Journal of Neural Transmission

, Volume 104, Issue 8–9, pp 887–894 | Cite as

Cognitive improvement during Tolcapone treatment in Parkinson's disease

  • M. Gasparini
  • E. Fabrizio
  • V. Bonifati
  • G. Meco
Parkinson's Disease and Allied Conditions


The aim of this study was to evaluate the effects of Tolcapone, a reversible, selective inhibitor of catechol-O-methyltransferase, on the cognitive functions of eight patients with advanced Parkinson's disease. They underwent neuropsychological and motor assessment at baseline and were reevaluated after 6 months. During this period, they received Tolcapone three times daily, while the L-dopa dosage was progressively reduced. Significant improvements were observed in the attentional task, auditory verbal short-term memory, visuo-spatial recall, constructional praxia and motor symptoms. These data suggest that treatment with Tolcapone, in combination with L-dopa therapy, may determine a significant improvement in cognitive resources of patients with advanced Parkinson's disease.


Tolcapone cognitive functions Parkinson's disease 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abraham W, Delanoy R, Dunn A, Zornetzer S (1979) Locus coeruleus stimulation decreases deoxyglucose uptake in ipsilateral cerebral cortex. Brain Res 172: 387–392PubMedGoogle Scholar
  2. Aston-Jones G, Foote S, Bloom F (1981) Norepinephrine containing locus coeruleus neurons in behaving rats exhibit pronounced responses to non-noxious stimuli. J Neurosci 1: 887–899PubMedGoogle Scholar
  3. Bowen F, Burns M, Yahr M (1976) Alterations in memory processes subsequent to short and long term treatmente with L-dopa. In: Birkmayer W, Hornykiewicz O (eds) Advances in parkinsonism. Roche, Geneva, pp 488–491Google Scholar
  4. Brown R, Marsden C, Quinn N, Wyke M (1984) Alteration in cognitive performance and affect-arousal state during fluctuations in motor function in Parkinson's disease. J Neurol Neurosurg Psychiatry 47: 454–465PubMedGoogle Scholar
  5. Cash R, Dennis T, L'Heureux R, Raisman R, Javoy-Agid F, Scatton B (1987) Parkinson's disease and dementia. Norepinephrine and dopamine in locus coeruleus. Neurology 37: 42–46PubMedGoogle Scholar
  6. Clark C, Geffen G, Geffen L (1986) Role of monoamine pathways in the control of attention: effects of droperidol and methylphendiate in normal adult humans. Psychopharmacology 90: 28–34PubMedGoogle Scholar
  7. Clark C, Geffen G, Geffen L (1989) Catecholamines and covert orientation of attention in humans. Neuropsychologia 27: 131–139PubMedGoogle Scholar
  8. Delis D, Direnfeld L, Alexander M, Kaplan E (1982) Cognitive fluctuations associated with on-off phenomena in Parkinson disease. Neurology 32: 1049–1052PubMedGoogle Scholar
  9. Fournet N, Moreand O, Roulin J-L, Naegele B, Pellat J (1996) Working memory in medicated patients with Parkinson's disease: the central executive seems to work. J Neurol Neurosurg Psychiatry 60: 313–317PubMedGoogle Scholar
  10. Gotham A, Brown R, Marsden C (1988) “Fontal” cognitive function in patients with Parkinson's disease “on” and “off” levodopa. Brain 111: 299–321PubMedGoogle Scholar
  11. Hietanen M (1991) Selegiline and cognitive function in Parkinson's disease. Acta Neurol Scand 84: 407–410PubMedGoogle Scholar
  12. Huber, S, Shulman H, Paulson G, Shuttleworth E (1987) Fluctuations in plasma dopamine level impair memory in Parkinson's disease. Neurology 37: 1371–1375PubMedGoogle Scholar
  13. Huber S, Shulman H, Paulson G, Shuttleworth E (1989) Dose-dependent memory impairment in Parkinson's disease. Neurology 39: 438–440PubMedGoogle Scholar
  14. Iversen S (1984) Cortical monoamines and behavior. In: Descarries L, Reader T, Jasper H (eds) Monoamine innervation and cerebral cortex. Liss, New York, pp 321–349Google Scholar
  15. Lezak M (1983) Neuropsychological assessment. Oxford University Press, New YorkGoogle Scholar
  16. Malapani C, Pillon B, Dubois S, Agid Y (1994) Impaired simultaneous cognitive task performance in Parkinson's disease: a dopamine-relate dysfunction. Neurology 44: 319–326PubMedGoogle Scholar
  17. Marsden C, Jenner P (1981) L-dopa's action in Parkinson's disease. Trends Neurosci 4: 148–150Google Scholar
  18. Mohr E, Fabbrini G, Ruggieri S, Fedio P, Chase T (1987) Cognitive concomitans of dopamine system stimulation in Parkinsonian patients. J Neurol Neurosurg Psychiatry 50: 1192–1196PubMedGoogle Scholar
  19. Mohr E, Fabbrini G, Williams J, Schlegel J, Cox C, Fedio P, Chase T (1989) Dopamine and memory function in Parkinson's disease. Mov Disord 4: 113–120PubMedGoogle Scholar
  20. Nutt J, Hammerstad J, Gancher S (1992) Drug therapy: protective therapy. In: Parkinson's disease. E Arnold, London, pp 54–57Google Scholar
  21. Owen A, James M, Leigh P, Summers B, Marsden C, Quinn N, Lange K, Robbins T (1992) Fronto-striatal cognitive deficits at different stages of Parkinson's disease. Brain 115: 1727–1751PubMedGoogle Scholar
  22. Owen A, Beksinska M, James M, Leigh P, Summers B, Marsden C, Quinn N, Sahakian B, Robbins T (1993) Neuropsychologia 31: 627–644PubMedGoogle Scholar
  23. Pillon B, Dubois B, Cusimano G, Bonnet A, Lhermitte F, Agid Y (1989) Does cognitive impairment in Parkinson's disease result from non-dopaminergic lesions? J Neurol Neurosurg Psychiatry 52: 201–206PubMedGoogle Scholar
  24. Pirozzolo F, Hansch E, Mortimer J, Webster D, Kuskowski M (1982) Dementia in Parkinson's disease. A neuropsychological analysis. Brain Cogn 1: 71–83PubMedGoogle Scholar
  25. Pollak P, Limousin P, Gervason C, Perret J (1993) Prolongation of levodopa-induced “on” motor periods by Ro 40-7592, a catechol-o-methyltransferase inhibitor in Parkinson's disease. Ann Neurol 34: 316Google Scholar
  26. Role L, Kelly K (1991) The brain stem: cranial nerve nuclei and the monoaminergic systems. In: Kandel E, Schwartz J, Jessell T (eds) Principles of neural sciences. Elsevier, Amsterdam, pp 680–700Google Scholar
  27. Shallice T (1982) Specific impairments of planning. Phil Transact Roy Soc Lond 298: 199–209Google Scholar
  28. Sharpe M (1992) Auditory attention in early parkinson's disease: an impairment in focused attention. Neuropsychologia 30: 101–105PubMedGoogle Scholar
  29. Scheibel A (1984) The brainstem core and sensory function. In: Darian-Smith I (ed) Handbook of physiology, section I, vol III, part 1. American Physiological Society, Bethesda, pp 243–256Google Scholar
  30. Scatton B, Javoy-Agid F, Rouquier L, Dubois B, Agid Y (1983) Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res 275: 321–328PubMedGoogle Scholar
  31. Weingartner H, Burns S, Diebel R, Lewitt P (1984) Cognitive impairment in Parkinson's disease: distinguishing between effort-demanding and automatic cognitive processes. Psychiatry Res 11: 223–235PubMedGoogle Scholar
  32. Zametkin A, Rapaport J (1987) Noradrenergic hypothesis of attention deficit disorder with hyperactivity: a critical review. In Meltzer H (ed) Psychopharmacology. Raven Press, New York, pp 837–842Google Scholar
  33. Zimmermann P, Sprengelmeyer R, Fimm B, Wallesch C (1992) Cognitive slowing in decision tasks in early and advanced Parkinson's disease. Brain Cogn 18: 60–69PubMedGoogle Scholar
  34. Zürcher G, Keller H, Kettler R, et al (1990) Tolcapone a novel, very potent, and orally active inhibitor of catechol-o-methyl-transferase: a pharmacological study in rats. Adv Neurol 53: 497–503PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1997

Authors and Affiliations

  • M. Gasparini
    • 1
  • E. Fabrizio
    • 1
  • V. Bonifati
    • 1
  • G. Meco
    • 1
  1. 1.Department of NeurosciencesUniversity “La Sapienza”RomeItaly

Personalised recommendations